In8bio Inc (NASDAQ:INAB) — Market Cap & Net Worth
Market Cap & Net Worth: In8bio Inc (INAB)
In8bio Inc (NASDAQ:INAB) has a market capitalization of $10.55 Million ($10.55 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27015 globally and #5599 in its home market, demonstrating a -0.93% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying In8bio Inc's stock price $1.07 by its total outstanding shares 9858383 (9.86 Million). Also see INAB current and non-current assets for a full breakdown of the balance sheet.
In8bio Inc Market Cap History: 2021 to 2026
In8bio Inc's market capitalization history from 2021 to 2026. Data shows change from $43.28 Million to $10.55 Million (-35.28% CAGR). Also see INAB cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
In8bio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #763 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2488 of 3165 |
Weight: In8bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
In8bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how In8bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of In8bio Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of INAB by Market Capitalization
Companies near In8bio Inc in the global market cap rankings as of September 18, 2026. Review INAB intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to In8bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
In8bio Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, In8bio Inc's market cap moved from $43.28 Million to $ 10.55 Million, with a yearly change of -35.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.55 Million | -54.27% |
| 2025 | $23.07 Million | +809.80% |
| 2024 | $2.54 Million | -81.36% |
| 2023 | $13.60 Million | -40.26% |
| 2022 | $22.77 Million | -47.38% |
| 2021 | $43.28 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of In8bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.55 Million USD |
| MoneyControl | $10.55 Million USD |
| MarketWatch | $10.55 Million USD |
| marketcap.company | $10.55 Million USD |
| Reuters | $10.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About In8bio Inc
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell… Read more